Daily Archives: November 26, 2019

A serving of Golden Rice contains half the beta-carotene children need daily.

By Erik StokstadNov. 20, 2019 , 3:00 PM

Soon. That has long been scientists' answer when asked about the approval of Golden Rice, a genetically modified (GM) crop that could help prevent childhood blindness and deaths in the developing world. Ever since Golden Rice first made headlines nearly 20 years ago, it has been a flashpoint in debates over GM crops. Advocates touted it as an example of their potential benefit to humanity, while opponents of transgenic crops criticized it as a risky and unnecessary approach to improve health in the developing world.

Now, Bangladesh appears about to become the first country to approve Golden Rice for planting. "It is really important to say we got this over the line," says Johnathan Napier, a plant biotechnologist at Rothamsted Research in Harpenden, U.K., who was not involved in the crop's development. He says approval would show that agricultural biotechnology can be successfully developed by publicly funded research centers for the public good. Still, environmental groups haven't dropped their oppositionand the first harvest isn't expected until at least 2021. And more research will be needed to show the extent of real-world benefits from Golden Rice.

Golden Rice was developed in the late 1990s by German plant scientists Ingo Potrykus and Peter Beyer to combat vitamin A deficiency, the leading cause of childhood blindness. Low levels of vitamin A also contribute to deaths from infectious diseases such as measles. Spinach, sweet potato, and other vegetables supply ample amounts of the vitamin, but in some countries, particularly those where rice is a major part of the diet, vitamin A deficiency is still widespread; in Bangladesh it affects about 21% of children.

To create Golden Rice, Potrykus and Beyer collaborated with agrochemical giant Syngenta to equip the plant with beta-carotene genes from maize. They donated their transgenic plants to public-sector agricultural institutes, paving the way for other researchers to breed the golden rice genes into varieties that suit local tastes and growing conditions.

Over the past 2 years, regulators in the United States, Canada, New Zealand, and Australia approved Golden Rice for consumption. There are no plans to grow the crop in these countries, but approval will prevent problems if Golden Rice somehow accidentally turns up in food supplies.

The Golden Rice under review in Bangladesh was created at the International Rice Research Institute (IRRI) in Los Baos, Philippines. Researchers bred the beta-carotene genes into a rice variety named dhan 29, which is grown widely during the dry season in Bangladesh and contributes about 14% of the national harvest. In tests of dhan 29 Golden Rice at multiple locations, researchers at the Bangladesh Rice Research Institute (BRRI) in Gazipur found no new farming challenges and no significant differences in qualityexcept for the presence of vitamin A.

BRRI submitted data to the Bangladeshi Ministry of Environment, Forest, and Climate Change in November 2017. The Biosafety Core Committee, a group of eight officials and scientists, has since been reviewing environmental risks, such as the plant's potential to become a weed, as well as food safety. The review is nearing completion; on 28 October, the Dhaka Tribune reported that a decision would be made by 15 November.

That date has come and gone; the holdup appears to be due to the death of a committee member. But a source familiar with the committee's deliberations says some members remain skeptical of Golden Rice, wondering for example why it is needed when people could also eat more vegetables.

Proponents are optimistic, however. The scientific evidence is strong, the committee previously approved another transgenic crop, and Golden Rice enjoys high-level political support in Bangladesh, they say. "We are hopeful that Golden Rice might get the green light soon," says Arif Hossain, director of Farming Future Bangladesh in Dhaka, which is funded by the Bill &Melinda Gates Foundation to inform policymakers and others about biotechnology.

After the environment ministry signs off, Golden Rice must be registered by a seed certification agency within the Ministry of Agriculture, which requires field trials in multiple places to test for seed quality. If all goes smoothly, farmers might have Golden Rice seed to plant by 2021.

How popular it will be is uncertain. Farmers in Bangladesh quickly adopted an eggplant variety engineered to kill certain insect pests after its 2014 introduction, but that crop offered an immediate benefit: Farmers need fewer insecticides. Golden Rice's health benefits will emerge more slowly, says agricultural economist Justus Wesseler of Wageningen University &Research in the Netherlands, so adoption may be slower as well. The government may need to promote Golden Rice and, Hossain says, even subsidize farmers to grow it.

Consumer acceptance may be another challenge, given the golden hue, says Sherry Tanumihardjo, who studies vitamin A and global health at the University of Wisconsin in Madison. "People have a difficult time changing the color of food they eat," and many people in Bangladesh prefer to eat white rice. On the other hand, cooked Golden Rice resembles khichuri, a popular dish of rice and lentils cooked with turmeric, which may increase its appeal. With Gates Foundation support, IRRI and BRRI are developing a strategy for directing farmers' harvest to rural regions and cities with high poverty and malnutrition rates.

Opposition from nongovernmental organizations could still hobble the introduction. Last month, two groups in Bangladeshthe Agricultural Farm Labour Federation and the National Women Farmers &Workers Associationcalled for a ban on both Golden Rice and transgenic eggplant.

If Golden Rice does make inroads in Bangladesh, additional varieties better adapted to other seasons or locations may follow. Bred at BRRI, they are now in greenhouse trials. Like all local versions of Golden Rice, these varieties were created not with genetic engineering, but by traditional backcrossing, so they will likely not need biosafety approval. "There will be no problem for a year-round supply of biofortified rice," says Partha Biswas, a plant breeder at BRRI.

But for now, all eyes are on dhan 29. "It would be great to see it approved," Napier says. "It's been a long time coming."

Read more here:
Bangladesh could be the first to cultivate Golden Rice, genetically altered to fight blindness - Science Magazine

In November 2018, controversial biophysics researcher He Jiankui from Shenzhen, China, announced the birth of the first-ever germline genetically-edited humans to universal condemnation as a serious breach of science, ethics and morality.

Chinese authorities suspended all his research activities that same month. And a few months later, he was fired from his job at the Southern University of Science and Technology (SUSTech) in Shenzhen.

But it was revealed in February 2019 these twins named Lulu and Nana might have inadvertently had their brains enhanced, raising fears about the arrival of superior genetically-engineered (GE) human beings.

His human gene-editing clinical experiment was conducted without public discussion in the scientific community. This revelation was first made public on Nov. 25, 2018, when MIT Technology Review published a story about his work. After the release of the MIT story, he released a promotional video about his work on YouTube, giving credence to speculation that he was interested in generating publicity for himself to satisfy his need for fame.

Now, Kevin Smith, a bioethicist at Abertay University in Scotland, said GE babies are highly desirable for disease protection. He also said gene editing is now such a low risk process, it could be used in human embryos.

Smith said his work is ethically justifiable. He said the work of this Chinese scientist could offer hope to parents at risk of transmitting serious genetic diseases to their children. Smith believes genetic engineering is the only conceivable way to handle embryos containing multiple disease-associated genes.

"If several common disorders could be avoided or delayed by genetically modifying humans, the average disease-free lifespan could be substantially extended," Smith said.

For the present, Smith recommended delaying genetic modification programs because society is largely opposed to genetically modifying humans. Despite this warning, Smith believes implementation of the process might be less than two years away or by 2021.

This October, research was published showing a new gene-editing technology could potentially correct up to 89 percent of genetic defects. Researchers said this includes genetic defects that cause diseases like sickle cell anemia.

Chinese scientist He Jiankui speaks at the Second International Summit on Human Genome Editing in Hong Kong on November 28, 2018. Reports indicated that China is banned from creating gene-edited babies. Anthony Wallace/AFP/Getty Images

See the original post here:
Genetically-Modified Babies Expected To Become A Reality In 2021 - Medical Daily

Three researchers have prepared a delightful concoction: equal parts plant science, cultural history and recipe book. The result is Botany at the Bar, an introduction to the fascinating world of bitters, complete with recipes for all manner of cocktails and elixers, prepared with the help of a mixologist. The three authors Selena Ahmed, an associate professor of sustainable food systems at Montana State University; Rachel Meyer, an assistant professor in ecology and evolutionary biology at UC Santa Cruz; and Ashley DuVal, a plant breeder who works on tropical tree cropsformed a company in 2011 called Shoots and Roots Bitters. They answered questions from Mind Matters editor Gareth Cook, and were gracious enough to share a specialty cocktail for Thanksgiving.

How did you get the idea of combining botany with craft cocktails?

AHMED: Our integration of botany and cocktails started when we were all graduate students through the New York Botanical Garden with fellowships and grants that emphasized broader impacts of science for society. As ethnobotanists who have carried out fieldwork in diverse communities around the world, we have encountered plants with fascinating attributes and cultural histories whose aromas and tastes captivate us.

I had just gotten back from Yunnan province of China where I had been studying biodiversity associated with tea production and consumption systems along ancient trade routes. Rachel had also been studying the origin and domestication of eggplants in this region. Ashley was examining diversity and management around acai in the Amazon. We were geeking out about some of the plants we had tasted such as nuo mi xiang cha. This plant is found around home gardens in Xishuangbanna prefecture of Yunnan and extracted and consumed as a tonic. It has a unique aroma reminiscent of sticky rice. We decided to collaborate on sharing samples of nuo mi xiang cha and others from our fieldwork as part of a research talk. This is when we tapped into our phytochemical lab protocols with the botanical infusion practices that we had seen in the field to make bitters that optimally bring out flavor and other plant compounds.

DUVAL: Presenting botanical research through drinks also created a forum for conversation. We learned even more about the plants from anecdotes that others shared with us. I remember a cocktail we made of goji berries and tartary buckwheat was found to be pleasant and reminiscent of home to a Nepalese couple; they described in detail the mouth feel and throat tickle from the goji berry infusion as an indicator of quality.

What do you mean by bitters?

DUVAL: Broadly defined, botanical bitters are infusions or extracts of plants that pull out their medicinal and flavor properties into a liquid. Most often, bitters are prepared by infusing botanical material in a fermented alcohol base including grain alcohol, fruit wine, or beer. This process serves to extract, concentrate and preserve the desired plant properties. Bitters can also be prepared by infusing plant material in nonalcoholic liquids such as water, as in the case of tea and tisanes as well as vinegar and fat.

People have been preparing bitters for thousands of years using plants from their surroundings for multiple purposes, and the infusions of plants in alcohol follows shortly after the innovation of fermentation arising in different parts of the world. Historically, bitters primarily had a medicinal function and evolved into key ingredients of cocktails. Although it has been used for over a thousand years, the term bitters is considered to have become popularized in its current meaning almost 300 years ago in England during the reign of King George II to market medicinal alcoholic products in response to government liquor taxes. Apparently, bitter herbs were added to liquor and sold as medicine as a way to escape taxation.

MEYER: Bitters serve a multifunctional role. Orally, they are taken for medicinal purposes including to aid in digestion, boost immunity, strengthen the body, for energy and for prevention of disease. Bitters also have an important social function in many cultures including for celebrating marriages and other life transitions. Bitters continue to play an important ritual function in many traditional communities. Traveling between villages in Togo, it was customary to stop and share bitters made from local herbs, along with local water, as a way to get acquainted with the area and culture, while they also provided a dose of restorative phytochemicals and hydration after the journey.

Can you tell me a bit about the bitters tradition in the United States?

DUVAL: In the U.S., everyone is most familiar with Angostura as a key ingredient for their Manhattan or Pink Gin. What people often dont realize is that Angostura, the oldest bitters brand in the United States, is also rooted in traditional knowledge, ethnobotany and herbal medicine. A German doctor, Johann Siegert from

Simn Bolvars army, was stationed in Venezuela in the 1820s, and developed a blend of local herbs he called amargo aromatico to improve appetite, digestion and other ailments the sailors and soldiers were afflicted with. The rest is history, but the contribution of local healers familiar with the medicinal plants of the region was not acknowledged in the development of the remedy. Of course this oversight was not uncommon for that timebut today we recognize the obligation we share to value traditional knowledge, and that this associated knowledge is important and vulnerable just like the plants.

Many of the bitter liquors that we are familiar with todayabsinthe, Chartreuse, Campari and Jgermeisterstarted out as patented medicines. Stoughtons elixir, created in 1712, were among the first medicines in England to receive a British royal patent and eventually became a successful British export to the American colonies. After the American Independence, local distillers in Boston and other cities began producing local versions of bitters and elixirs previously imported from Europe. Lash's Bitters Company was one of the successful bitters companies in the United States during the 20th and early 21st century that show the evolving use of bitters from a medicine to an alcoholic beverage. Early ads in 1901 show a little boy needing to use the chamber pot, promoting its use for digestion and constipation, but an ad in the 1920s suggests its use as a night cap.

AHMED: I live in Bozeman, Mont. The whole landscape is rife with medicinal and bitter plants with unique flavors such as bitter root, camas, chokecherries, service berries, huckleberries, wild rose, ponderosa pine and Rocky Mountain juniper. Native American communities have been making infusions of many of these plants for centuries both as a well-being practice and for purifying the spirit. The bitters tradition in the United States is a juxtaposition of this long use of botanicals by Native American communities along with the assimilation of people from around the world who have made this their home.

When you look at someone sipping on a drink today, what parallels do you see to someone, say, 1,000 years ago, sipping on a bitters concoction?

DUVAL: Sometimes it is more than a parallel; often we are actually enjoying the same beverages. Many of the worlds earliest bitters and botanical infusions are still widely consumed today or enjoying a revival. Mead, a spiced beverage from fermented honey and water, and the mulled apple cider we enjoy around the holidays connect us to the very first documented uses of wine, which were spiced with herbs as medicine or preservatives. There is also an enormous revival of interest in tonics for health, and options for beverage bars such as kava bars that dont serve alcohol but still offer the social ritual experience.

AHMED: Many of the plants are the same as well as their functionality. For example, Chinese materia medicas from 1,5002,000 years ago include hundreds of plants in which dozens are used in drinks today such as great yellow gentian, ginseng and cinnamon bark. There are hundreds of gentian species, with the root of Gentiana lutea being a key ingredient of apritifs, bitters, liqueurs and tonics to this day. Gentians have long been used for treating and preventing digestive issues. We see these overlaps of plants used past and present in regions around the world. For example, hops, American ginseng and wild black cherry were common plants used by several Native American groups and are found as ingredients of bitters today.

Would you be so kind as to suggest a cocktail for a Thanksgiving Day?

MEYER: Thanksgiving may first bring to mind turkey. As enthusiasts of domestication history, we love that many places where early turkey domestication took place displayed concurrent agave domestication. This spans Veracruz and Jalisco to Arizona. But to many who have to prepare a Thanksgiving meal, they might first think of the stress of handling cooking, family politics and everyones entertainment, so lets make a boozy drink with lots of Agavaceae species that also provides those gracious overworked hosts with some nutrition and a dose of antianxiety, endurance-boosting adaptogens that will kick in immediately.

This cocktail, which we developed with the mixologist Christian Schaal, features chestnuts as part of a chestnut pepita orgeat. In the U.S., only those of us living in the Pacific Northwest might be able to access the American chestnut (Castanea dentata), a towering tree that used to be widespread but was wiped out by a disease. Now, after decades of work spearheaded by William Powell at State University of New York, the American chestnut has just become the first GMO tree to be approved for release, just this year, and its expected to replenish our forests and orchards. We find this is one of the most beautiful examples of genetic engineering to de-extinct species and restore ecosystems.

Cocktail name: The good genePreparation time: 1 hourDrinks: infusions are enough for >10 drinks and can be saved, refrigerated, for up to two weeksIngredients:Ingredients for infusing350 mg of powdered Rhodiola (Rhodiola rosea)this plant is stress-fighting adaptogen becoming popular in the natural products industry and as a new crop in arctic areas facing climate change. Its rosavin and salidroside contribute to the functionality of the drink. This arctic species is common to find as a ground root powder that can be consumed as a tisane or in capsules. For this drink, we just broke open two gel capsules.1/8 tsp cinnamon (Cinnamomum verum) an Indonesian tree brought to Mexico by the Spanish1/2 cup, or about 10 chestnuts (Castanea sppthere are six species to choose from, and soon maybe youll have the American chestnut available to make this drink!) cup pepitas (Styrian pumpkin seeds, Cucurbita pepo) green seeds that have no hull, descended from a pumpkin with a special mutation that was discovered in Austria. Pumpkins of this species originated in mesoamerica (along with turkeys and agaves).Pinch of salt1 pint of sugar1 pint of water3 oz tequila (Agave tequilana) a bright, likely familiar, nectar-like spirit from JaliscoEquipment: blender, fine mesh strainer, cup, spoonFor the rest of the drink1 oz mezcal per drink (Agave spp)an oft smoky, complex spirit made from one to several of over 30 agave species0.5 oz sotol per drink (Dasylirion spp)a grassy, earthy spirit made from species in a genus related to Agave0.5 oz lime juice, lime peel for garnishIceEquipment: Shaker, fine mesh strainer, coup glass

Prepare the infused tequila: Mix tequila, cinnamon, and rhodiola in a cup, let sit for 45 minutes, strain to retain liquid. During that infusing time, you can prepare the orgeat.

Prepare the orgeat: Make a simple syrup by boiling 1 pint of water and 1 pint of sugar. Refrigerate to cool. With a paring knife, score an X on the round side of the chestnuts, soak chestnuts in water for 1 minute, lay scored side up on a baking tray, and bake at 400 degrees F for 20 minutes or until cooked through. Peel the chestnuts immediately. Dont worry about the papery layer between the seed and the shell. Toast the pepitas on the stove or in the oven until fragrant. Put the chestnuts, pepitas, simple syrup, and a pinch of salt in the blender and blend until fully homogenized. Let rest 15 minutes, strain to retain the liquid.

To prepare one cocktail: Add 0.75 oz orgeat, 0.5 oz lime juice, 0.25 oz infused tequila, 1 oz mezcal, and 0.5 oz sotol to a shaker with ice, shake, and pour over the fine mesh strainer into a coup glass. Garnish with a lime peel on the glass rim.

Continued here:
Botany at the Bar - Scientific American

The new report has been added to Reportocean.coms offering. For more info click here @https://www.reportocean.com/industry-verticals/details?report_id=4575

This ready to use report offers you detailed insight into the global genetic engineering industry with market size, in value terms, estimated at USD million/billion for the period. It also provides the projected growth rate for the next 56 years along with forecast market value. The study includes estimation of market size, detailed profile of products/services, SWOT of manufacturers/providers, their strategies, and recent developments in the industry. In brief the Global Genetic Engineering Market 2019 research report by Report Ocean offers industry data, trends, qualitative information, and competitive landscape, not easily accessible, and culled from multiple sources so that it acts as a ready recknor for you. The report is in-depth, authentic, exhaustive and very exclusive.

Takeaways from the Report:

You will learn about the market drivers for the projected period

You will get to know about the headwinds hampering the market growth

You will be exposed to the segment-region-wise analysis of major geographical areas, viz, North America, Latin America, Europe, Asia-Pacific, and the rest

You will know the market size at the country level

You will get detailed insight into the strategic and actual happenings of the key players in the genetic engineering industry, including research and developments, collaboration, working partnership, and other acts, product launches, etc.

You will be provided details of various segments

You will also be enlightened about the value and supply chain analysis of the market

Parameters for the Study:

The exhaustive study has been prepared painstakingly by considering all possible parameters. Some of these were

Consumers options and preferences

Consumer spending dynamics and trends

Market driving trends

Projected opportunities

Perceived challenges and constraints

Technological environment and facilitators

Government regulations

Other developments

Research Methodology:

While preparing the study of global genetic engineering market for the reference year, we took recourse to collect qualitative and quantitative information based on primary sources (nearly 80% weightage) through personal interactions, and secondary research, along with consultation with industry level professionals and experts. Historical trends and current market estimates were arrived at and analyzed to predict the likely direction in which the market will move in the next 56 years.

The report also studies the varying trends of diverse segments and subcategories, presented geographically, based on primary and secondary research. These are cross-checked by interviewing the key level decision-makers, such as CEOs, VPs, Directors, etc. of the relevant companies at the top and mid-size segments; this leads to gaining of more profound insights into the market and industry performance, which in turn authenticates and substantiates the findings.

Secondary research mainly focused on identifying, collecting, collating, and analyzing information needed for an extensive, market-oriented, commercial, and client-friendly study of the genetic engineering market. This result also led to generating information about the major players, market classification, and segmentation according to the industry trends, geographic locations, and technological developments related to the market. Our team of field force and deck-based researchers gathered information from various credible sources such as annual reports of the companies, filings with regulatory agencies, journals, white paper, corporate presentations, company websites, paid database, and many more. In addition to sources like Hoovers, Factiva, Bloomberg, Report Linker, we used our in-house database to generate a very very trustworthy report.

We followed, concurrently, both the Bottom-Up approach and Top-Down approach. Under the former, we assessed the market size of individual markets by performing primaries and secondaries of major countries which hold around 7580% of the regional market share. Then we extrapolated the same to derive the projected size of any specific region such as Americas, Europe, Asia-Pacific, etc. Under the latter approach, first, we estimated the size of the global market and then broke it down at specific country level. After performing both the processes, we invoke gap analysis, where we identify the deviation/differences in market size at the country, regional, and global level. Then through having relook at data sources, data, and analytics we rework on the report so that no gap remained. Ultimately both the approaches should yield the same output

The report, in short, is very rigorously prepared and is as authentic and reliable as it can be.

Continue

View Full Report Detail and Table of Content athttps://www.reportocean.com/industry-verticals/details?report_id=4575

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=4575

Summary

Global Genetic Engineering Market to reach USD XX billion by 2025.

Global Genetic Engineering Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The major driving factor of global Genetic Engineering market are surging utility of technologies such as CRISPR, Talen & ZNF and rising focus on innovation in Gene Therapy in Genetic Engineering. In addition, increasing funding for research and development of medical products is the some other driving factor that drives the market. However, one of the major restraining factors of Genetic Engineering market is high amount of investment. Genetic engineering is also known as genetic modification or genetic manipulation. It is the direct manipulation of an organisms genes using biotechnology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. Genetic engineering allows of plant or animals to be modified so their maturity can occur at a quicker pace. Genetic modification can also help to create resistance to common forms of forms of organism death. Genetic engineering can also change the traits of plants or animals so that they produce greater yield per plant. Any genetic mutation caused by environmental mutagens may also be corrected through genetic engineering.

The regional analysis of Global Genetic Engineering Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America has dominate the market of total generating revenue with 40% across the globe in 2016 due to increasing use of genetic engineering for use of gene therapy, high incidence of cancer and increasing awareness for the use of stem cells. Europe is also contributing second largest major share in the global market of Genetic Engineering. Asia-Pacific ..continue..

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=4575

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or country-based analysis can be provided as a part of customization

Follow us on:

Facebook: https://www.facebook.com/reportocean

Twitter: https://twitter.com/reportocean

LinkedIn: https://in.linkedin.com/company/reportocean

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Sandeep SinghEmail:sales@reportocean.com

Read more:
Recent Market Report on Global Genetic Engineering Market is slated to grow rapidly in the coming years - TheFinanceTime

DUBLIN--(BUSINESS WIRE)--The "Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ResearchAndMarkets.com's offering.

Global Recombinant Plasma Protein Therapeutics Market: Overview

This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Moreover, increase in the number of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid adoption of genetic engineering technologies in healthcare for the development of new therapeutics are also estimated to fuel the market during the forecast period.

The global recombinant plasma protein therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, cell line, indication, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global recombinant plasma protein therapeutics market.

New product launch and FDA approvals are also important factors that are expected to boost the market across the globe. For instance, in April 2018, Shire received FDA approval for VONVENDI recombinant von Willebrand factor indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD)

Key Topics Covered:

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market

4. Market Overview

4.1. Introduction

4.1.1. Product Definition

4.1.2. Industry Evolution/Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016-2026

5. Key Insights

5.1. New Product Launch and Regulatory Approvals

5.2. Key Mergers & Acquisitions

5.3. Regulatory Scenario by Region/Country

6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings/Developments

6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class

7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line

7.1. Introduction & Definition

7.2. Key Findings/Developments

7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line

8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication

8.1. Introduction & Definition

8.2. Key Findings/Developments

8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication

9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region

9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region

10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

10.1. Introduction

10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016-2026

10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

12.1. Introduction

12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

13.1. Introduction

13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

14.1. Introduction

14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

15. Competitive Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)

15.2. Market Share Analysis By Company (2016)

15.3. Company Profiles

15.3.1. CSL Limited

15.3.2. Shire (Takeda Pharmaceutical Company Limited)

15.3.3. Octapharma

15.3.4. Novo Nordisk A/S

15.3.5. Bayer AG

15.3.6. Pfizer Inc.

15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)

15.3.8. Aptevo Therapeutics

15.3.9. Pharming Group NV

For more information about this report visit https://www.researchandmarkets.com/r/4aj3c2

Read more here:
Global Recombinant Plasma Protein Therapeutics Market - Industry Analysis, Size, Share, Growth, Trends & Forecast 2018-2026 -...